Avian Influenza

Infectious Diseases
7
Pipeline Programs
3
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 5 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
1
3
A/H7N9Phase 21 trial
AS03Phase 21 trial
AS03Phase 21 trial
H5 AC-Anhui RNA VaccinePhase 1Vaccine1 trial
Active Trials
NCT07019883Active Not RecruitingEst. May 2026
NCT03682120CompletedEst. Apr 2020
NCT02921997CompletedEst. Feb 2018
+1 more trials
Novartis
NovartisBASEL, Switzerland
1 program
1
H5N1 influenza vaccinePhase 2Vaccine1 trial
Active Trials
NCT00561184Completed47Est. Jun 2008
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
2 programs
2
ND1.1Phase 11 trial
ND1.1Phase 11 trial
Active Trials
NCT01335347CompletedEst. Sep 2012
NCT01698060CompletedEst. Nov 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsA/H7N9
Allergy TherapeuticsAS03
Allergy TherapeuticsAS03
NovartisH5N1 influenza vaccine
Allergy TherapeuticsH5 AC-Anhui RNA Vaccine
VaxartND1.1
VaxartND1.1

Clinical Trials (7)

Total enrollment: 47 patients across 7 trials

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Start: Nov 2018Est. completion: Apr 2020
Phase 2Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Start: Feb 2018Est. completion: Jul 2019
Phase 2Completed

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Start: Nov 2016Est. completion: Feb 2018
Phase 2Completed
NCT00561184NovartisH5N1 influenza vaccine

Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine

Start: Oct 2007Est. completion: Jun 200847 patients
Phase 2Completed
NCT07019883Allergy TherapeuticsH5 AC-Anhui RNA Vaccine

A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

Start: Jun 2025Est. completion: May 2026
Phase 1Active Not Recruiting

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

Start: Sep 2012Est. completion: Nov 2013
Phase 1Completed

Safety Study of an Oral Vaccine to Prevent Avian Influenza

Start: Apr 2011Est. completion: Sep 2012
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space